R01 CA107082/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	6
2009	6
2010	19
2011	11
2012	14
2013	7
2014	4
2015	3
2016	1
2022	0

1

Recent clinical experience with oncolytic viruses.

Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. Donnelly OG, et al. Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. doi: 10.2174/138920112800958904. Curr Pharm Biotechnol. 2012. PMID: 21740364 Review.

2

The hitchhiker's guide to virotherapy.

Donnelly O, Vile R, Pandha H, Harrington K, Melcher A. Donnelly O, et al. Oncotarget. 2012 Aug;3(8):735-6. doi: 10.18632/oncotarget.627. Oncotarget. 2012. PMID: 22964541 Free PMC article. No abstract available.

3

Oncolytic viruses: a novel form of immunotherapy.

Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Prestwich RJ, et al. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581. Expert Rev Anticancer Ther. 2008. PMID: 18925850 Free PMC article. Review.

4

The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R, Harrington K. Hingorani M, et al. Curr Cancer Drug Targets. 2010 Mar;10(2):242-67. doi: 10.2174/156800910791054194. Curr Cancer Drug Targets. 2010. PMID: 20201784 Free PMC article. Review.

5

Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Willmon C, et al. Mol Ther. 2009 Oct;17(10):1667-76. doi: 10.1038/mt.2009.194. Epub 2009 Aug 18. Mol Ther. 2009. PMID: 19690519 Free PMC article. Review.

6

Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, Harrington KJ. Pencavel T, et al. Gene Ther. 2010 Aug;17(8):949-60. doi: 10.1038/gt.2010.48. Epub 2010 May 6. Gene Ther. 2010. PMID: 20445580 Free PMC article. Review.

7

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Harrington KJ, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. doi: 10.1016/j.cytogfr.2010.02.006. Epub 2010 Mar 12. Cytokine Growth Factor Rev. 2010. PMID: 20223697 Free PMC article. Review.

8

What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?

Donnelly OG, Melcher AA, Vile RG, Pulido J. Donnelly OG, et al. Immunotherapy. 2012 Aug;4(8):749-51. doi: 10.2217/imt.12.65. Immunotherapy. 2012. PMID: 22947000 Free PMC article. No abstract available.

9

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Pulido JS, Pulido JE, Michet CJ, Vile RG. Pulido JS, et al. Retina. 2010 Jan;30(1):1-5. doi: 10.1097/IAE.0b013e3181cde727. Retina. 2010. PMID: 20061905 Free PMC article. No abstract available.

10

Oncolytic viruses: now interviewing for the all-star game.

Vile R. Vile R. Mol Ther. 2010 May;18(5):866-8. doi: 10.1038/mt.2010.60. Mol Ther. 2010. PMID: 20436492 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results